Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.11% | 10.10% | 9.70% | 10.10% | 11.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.11% | 10.10% | 9.70% | 10.10% | 11.65% |
| Cost of Revenue | 11.60% | 10.36% | 7.37% | 5.37% | 6.75% |
| Gross Profit | 8.20% | 9.76% | 12.83% | 16.70% | 18.60% |
| SG&A Expenses | 6.72% | 8.38% | 7.35% | 6.03% | 5.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.71% | 9.80% | 8.05% | 6.34% | 6.42% |
| Operating Income | -6.07% | -7.21% | 4.67% | 19.22% | 25.66% |
| Income Before Tax | -36.68% | -42.79% | -26.39% | 13.63% | 16.91% |
| Income Tax Expenses | -15.08% | 75.20% | 71.12% | 84.42% | 78.65% |
| Earnings from Continuing Operations | -37.22% | -45.98% | -32.46% | 7.89% | 10.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.22% | -45.98% | -32.46% | 7.89% | 10.51% |
| EBIT | -6.07% | -7.21% | 4.67% | 19.22% | 25.66% |
| EBITDA | -1,064.91% | -1,005.62% | 24.27% | 96.21% | 103.57% |
| EPS Basic | -35.69% | -44.27% | -30.91% | 8.79% | 11.33% |
| Normalized Basic EPS | -15.59% | -16.50% | 3.33% | 21.14% | 30.39% |
| EPS Diluted | -35.02% | -43.55% | -29.92% | 8.70% | 11.70% |
| Normalized Diluted EPS | -15.59% | -16.50% | 3.33% | 21.14% | 30.39% |
| Average Basic Shares Outstanding | 1.14% | 1.09% | 1.05% | 0.96% | 0.92% |
| Average Diluted Shares Outstanding | 1.14% | 1.09% | 1.05% | 0.96% | 0.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |